CareTrust REIT, Inc. (CTRE)
Assessment summary
Investable with eyes open — watch the weaker categories.
Compare peers
Healthcare names covered in the tracker.
Price
$40.84
Yield
3.55%
P/(A)FFO
21.27x
Payout
1.32x
Occupancy
—
Net debt / EBITDA
0.60x
Category scores
Six weighted categories make up the overall quality score. Each renders its own rationale once this name has been through a scoring pass.
Cash flow & dividend safety
AFFO per share (Normalized FAD) grew 12% year-over-year to $0.48 in Q1 2026, with full-year 2026 guidance projecting 13.6% growth over 2025 results, demonstrating steady growth momentum. The payout ratio stands at approximately 81% of Normalized FAD, comfortably below the 75% threshold and well within safe territory. The dividend was increased 16.4% year-over-year in Q1 2026, reflecting consistent capital returns to shareholders. However, the score falls short of 5 because the data does not confirm a 10+ year dividend growth streak—only recent quarterly increases are documented.
Balance sheet
CareTrust demonstrates fortress-level balance sheet strength well above the 5-point rubric threshold. Net debt-to-EBITDA of 0.6x is substantially below the ~5x anchor, indicating minimal leverage. Payout coverage of 1.32x (FFO-to-dividend) exceeds the 4x+ coverage benchmark, with normalized FAD payout at 81% leaving substantial cushion. The company achieved investment-grade rating upgrade from Moody's, confirming BBB+ or better credit quality. Debt structure shows no maturities until 2028, providing a laddered maturity profile with $1.2 billion revolving credit facility and $879 million ATM capacity, supporting financial flexibility for continued growth investments.
Operating performance
CareTrust demonstrates strong operating performance with Normalized FFO per share increasing 14% year-over-year to $0.48 in Q1 2026, and full-year 2026 guidance projecting 14.8% FFO growth. The company achieved 100% collection of contractual rent and interest, closed $1.1 billion in investments year-to-date at 8.9% blended yield, and increased its quarterly dividend 16.4% year-over-year. While occupancy data is not provided in the materials, the consistent investment activity, strong FFO growth, and management commentary about momentum across all growth engines indicate performance exceeding the 3-anchor threshold of flat-to-+2% SSNOI growth and stable low-90s occupancy, placing the company in the 4-5 range rather than the 5-anchor requirement of 3%+ SSNOI growth with 95%+ occupancy.
Portfolio & sector quality
CareTrust operates in skilled nursing and senior housing—a structurally challenged sector facing reimbursement pressure, labor cost inflation, and regulatory headwinds. The portfolio spans the US and UK with exposure to multiple operators, providing some diversification, but the underlying sector remains competitive with aging demographics and oversupply in many markets. Management demonstrates strong execution (14% FFO growth, $1.1B invested YTD at 8.9% yield, investment-grade upgrade) and maintains fortress-like leverage (0.6x net debt-to-EBITDA), but these operational strengths do not offset the sector's structural challenges. The company is not positioned in a secular-tailwind market, and asset quality/market dynamics reflect competitive rather than supply-constrained conditions.
Management & capital allocation
CareTrust demonstrates internal management with a self-administered structure and shows mixed capital allocation discipline. FFO per share grew 14% year-over-year to $0.48, and guidance projects 14.8% FFO growth for 2026, indicating per-share accretion. However, the company employed $129.5 million in equity forward contracts (ATM program) during Q1 and settled $363.6 million post-quarter, representing material dilutive issuance despite strong operational performance. The payout ratio of 81% on FAD and dividend increase to $0.39 per share (16.4% YoY) suggest shareholder-friendly capital allocation, but the aggressive use of equity financing alongside $1.1 billion in year-to-date investments indicates growth is being funded partly through dilution rather than accretion-only issuance. Disclosure appears candid with detailed guidance assumptions and transparent leverage metrics (0.6x net debt-to-EBITDA).
Valuation
Valuation scored against the same-category peer cross-section (peer_fallback) from this nightly pass, because this name has fewer than 8 own-history points so far.
Score history
Event-anchoredIllustrative history — each point corresponds to a scoring trigger (filing, announcement, or initial coverage). At launch a name has a single point.
Sources
Sources are the exact documents used by this assessment, recorded when it ran.
Metric history
P/(A)FFOP/(A)FFO over time — 25 data points since Aug 2, 2026.
Scores are analytical opinions, not investment advice. Figures reflect the most recent data available as of the assessed date and may differ from current market values.